Developing screening methods for inhibitor screens of HIF hydroxylases is an enormous challenge, as these are metalloenzymes. My group combines spectroscopy, crystallography, and medium-throughput binding assays to screen for inhibitors.
Activating enzymes would open up new directions for discovering disease pathways. Enzyme delivery is one approach, presenting new opportunities for therapeutics. We are collaborating with nanotechnology researchers to target active enzymes into cells.